![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bioprogress | LSE:BPRG | London | Ordinary Share | GB0032681628 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 50.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:2058C BioProgress PLC 16 August 2007 For Immediate Release 16 August 2007 BioProgress Plc Approval for SoluPol(TM) enabled Hypozalix(TM) London UK, 16 August 2007, BioProgress (AIM: BPRG), the specialty pharmaceutical and healthcare company announces the gaining of Medical Device approvals from an EU Notified Body for two novel line extensions of the Artisial / Hypozalix(TM) brand using SoluPol(TM) technology. This regulatory approval equates to authorisation to sell the products to the general public in Europe and certain other markets such as South America and the Middle East. The endorsement also represents a further validation of the core enabling technology of the Group. Artisial / Hypozalix(TM) is BioProgress' proprietary product for the treatment of xerostomia (dry mouth). The two new formulations are a liquid mouthwash and oral gel designed to re-hydrate the oral mucosa. This range compliments the existing oral spray product and fits within the Group's sore mouth franchise. The range allows BioProgress to compete more effectively in salvia replacement market with planned extension into the oral healthcare market. Xerostomia, the first indication, is a dry mouth condition caused by a lack of production of saliva. It is estimated to affect between 10 and 24 per cent of the adult population and up to as much as 46 per cent of elderly people. It is also disease related and is often a known side effect of drug therapy. In addition to the two new Hypozalix products, the new approved formulations together with the originator sprays will be marketed by Melbrosin, the OTC division of the Group. This marketing initiative will utilize the Menoflavon brand, targeting xerostomia associated with menopausal symptoms. The product will be made available for the whole of the existing Menoflavon distribution system. The line, brand and range extensions approved for marketing will be available both as prescription as well as over the counter medicines. It is expected these will be launched in Q4 2007. Steve Martin, Chief Development Officer, BioProgress said: "The approval of two new line extensions using our polymer technology is clear validation that BioProgress is able to take products from concept through to market. The integration between the different sites has gone smoothly as evidenced by the Melbrosin division being able to launch products from our development pipeline." Richard Trevillion, Chief Executive Officer, BioProgress said: "Once again this accreditation demonstrates the strength of the Company's development pipeline. We are continually proving our ability to apply our enabling technologies to make products that reach the market and are able to deliver revenues which further increase shareholder value." For further information: BioProgress Plc + 44 (0) 20 7098 9881 Richard Trevillion, CEO Steve Martin, CDO Hiral Patel, CFO Buchanan Communications + 44 (0) 20 7466 5000 Rebecca Skye Dietrich Mark Court About BioProgress BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical and healthcare products. The business continues to develop innovative delivery mechanisms using its XGEL(TM) polymer technology. For further information please go to www.bioprogress.com This information is provided by RNS The company news service from the London Stock Exchange END MSCSFLEDISWSEEA
1 Year Bioprogress Chart |
1 Month Bioprogress Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions